Table 2.
Scenario | Year of vaccine introduction | Maximum coverage | Durability of vaccine-derived immunity |
---|---|---|---|
1 | Country-specific (2022 - 2034) | Country-specific (9 - 99%) | Full efficacy for 10 years |
2 | Country-specific (2022 - 2034) | Country-specific (9 - 99%) | Linear waning over 20 years |
3 | 2022 | 50% | Full efficacy for 10 years |
4 | 2022 | 50% | Linear waning over 20 years |
5 | Country-specific (2022 - 2034) | 50% | Full efficacy for 10 years |
6 | Country-specific (2022 - 2034) | 50% | Linear waning over 20 years |
Potential vaccination scenarios for varying years of vaccine introduction, coverage, vaccine-derived immunity dynamics, and age of vaccination (at birth or 5 years of age).